The migraine medication erenumab looks to pose no elevated probability of hypertension, easing earlier issues that this might per chance per chance in all probability moreover very effectively be one in all the drug’s negative events, an prognosis of postmarketing files display hide. Alternatively, investigators display hide that more compare is wished to substantiate that this is the case.
Whereas randomized clinical trials admire proven no elevated probability of hypertension connected to the drug, it has been reported in postmarketing files. Nonetheless, a bunch of those events happened in sufferers with beforehand documented hypertension or probability factors for the disorder, the investigators display hide.
The price of hypertension negative events in postmarketing files was 0.144 per 100 particular person-years. Most such reports described finest one instance of elevated blood strain. In April 2020, the prescribing files for the drug was updated to consist of a mention of the probability of hypertension.
Dr David Dodick
“Given the boundaries of postmarketing reports, including incomplete files, lack of a preserve watch over arm, and others, extra files are actually wished to fully symbolize the nature, the timing, and the extent to which hypertension is a probability connected to erenumab, and indeed diverse [calcitonin-gene-related peptide (CGRP)] pathway antagonists,” acknowledged gape investigator David W. Dodick, MD, professor of neurology on the Mayo Health heart School of Treatment in Phoenix, Arizona.
The findings had been presented on the digital American Headache Society (AHS) Annual Assembly 2021.
No Increased Threat Over Time
A monoclonal antibody and CGRP antagonist, erenumab is current in the US for migraine prevention in adults. CGRP medications are vasodilators and, subsequently, migraine treatments that hear to this pathway would per chance per chance in all probability moreover theoretically admire hypertensive effects.
To assess the probability of hypertension in migraine sufferers treated with erenumab, investigators examined clinical trial and postmarketing files. The prognosis included cases with restricted files and sufferers with a clear etiology for the come of hypertension.
The exhaust of Amgen Clinical Trial files, the researchers performed a pooled security prognosis of four placebo-controlled, double-blind share 2 or 3 compare of the drug. Contributors had episodic or chronic migraine and had been between ages 18 and 60 years or age 65 years. The doses studied had been 70 mg and 140 mg.
In these compare, blood strain files for every affected person had been basically based fully fully on a imply of a minimum of two measurements taken after sufferers had been in rested teach for a minimum of 5 minutes. The position used for blood strain measurement for every affected person was fixed in the heart of the gape.
The investigators also analyzed postmarketing reports of hypertension from May per chance well 17, 2018, to January 31, 2020, identified in Amgen World Security files.
The pooled compare included 1043 individuals receiving placebo, 893 receiving 70 mg of erenumab, and 507 receiving 140 mg of the drug. Throughout the therapy share, the incidence of hypertension was 0.9% among controls, 0.8% in the 70-mg community, and nil.2% in the 140-mg community. The proportion of sufferers who began a brand contemporary antihypertensive medication was 1.2% in controls, 0.8% in the 70-mg community, and nil.2% in the 140-mg community.
In a prolonged-term, delivery-be conscious gape, sufferers with episodic migraine bought erenumab therapy for up to 5 years. The incidence of hypertension did no longer amplify with time in this inhabitants.
The postmarketing files encompassed 245,682 particular person-years of erenumab exposure The researchers identified 362 hypertension events (355 cases). The price of those events was 0.144 per 100 particular person-years. The exposure-adjusted incidence of hypertension was 1.9 per 100 affected person-years for erenumab.
Of the 362 hypertensive events, 158 (43.6%) had been in sufferers with a clinical history of hypertension or probability factors for hypertension. Records referring to the time to onset of hypertension was accessible for 121 (33.4%) negative events.
Of this community, 56 (46.2%) happened inner 1 week of erenumab initiation, including 43 (35.5%) that happened inner 1 day. This snappy time to hypertension onset “is inconsistent with the pharmacokinetic profile of once-month-to-month erenumab 70 mg or 140 mg, which has a prime serum concentration in roughly 6 days,” acknowledged Dodick.
Hypertension “Not a Barrier” to Therapy
Commenting on the findings for Medscape Clinical Records, Richard B. Lipton, MD, Edwin S. Lowe professor and vice chair of neurology at Albert Einstein School of Treatment in the Bronx, Fresh York, illustrious that whereas in belief blocking off CGRP would per chance per chance in all probability moreover amplify blood strain. Nonetheless, he illustrious that the records and clinical expertise invent no longer suggest erenumab poses a necessary probability.
Dr Richard Lipton
“I in point of fact admire infrequently viewed contemporary onset hypertension with erenumab in the sufferers treated at our clinical heart. The few cases I in point of fact admire viewed had been in older adults with pre-existing hypertension,” he acknowledged.
The investigators’ overview of clinical trial files, at the side of global security databases was a energy of their gape, acknowledged Lipton. In clinical trials, sufferers are monitored fastidiously, and a placebo preserve watch over community aids in the resolution of background charges.
“In the trials, the incidence of up-to-the-minute-onset hypertension or hypertension exacerbation was 0.9%, whereas the placebo price was 0.2%,” acknowledged Lipton. “The absolute amplify in the probability of hypertension was 0.6% or six cases per thousand: a low price.” Nonetheless clinical trials be half of fastidiously selected sufferers who invent no longer signify the mammoth community of oldsters treated with erenumab in clinical practice, he added.
The global security files are more representative of sufferers who receive erenumab in exact-world settings. The weaknesses of those files, though, are the shortcoming of a preserve watch over community and the incomplete ascertainment of files connected to spontaneous reporting.
Yet both sorts of compare, with their complementary strengths and weaknesses, indicated low charges of hypertension.
“The low incidence of hypertension, in my witness, is no longer a barrier to the utilization of erenumab, though checking blood strain after initiating any contemporary migraine therapy is prudent,” Lipton concluded.
The gape was funded by Amgen. Dodick had no connected disclosures. Lipton has consulted for and performed compare funded by Amgen and by diverse firms that fracture CGRP pills. He has inventory alternate suggestions in Biohaven.
American Headache Society (AHS) Annual Assembly 2021: Summary IOR-08. Supplied June 3, 2021.
Prepare Erik Greb on Twitter: @MedscapeErik.
For more Medscape Neurology files, be half of us on Facebook and Twitter.
